Physician profile
Oswald Bostic
NPI 1063439586
$2,772.32
in general payments reported to CMS, 2019-2025
19 companies · $63.97 in 2025
The $63.97 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $593 · 2021: $448 · 2022: $852 · 2023: $85.61 · 2025: $63.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $85.61 · Debt Forgiveness: $63.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $85.61 |
| Debt Forgiveness | $63.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $683.52 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $306.97 | 2019-2023 | Farxiga |
| Amgen INC. | $285.72 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $235.41 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $206.32 | 2021-2023 | Verquvo |
| Arbor Pharmaceuticals, INC. | $192.74 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $146.36 | 2020-2023 | Eliquis |
| Pfizer INC. | $144.71 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.73 | 2022 | |
| Baxter Healthcare | $63.97 | 2025 | |
| Esperion Therapeutics, INC. | $38.30 | 2020-2021 | |
| Novo Nordisk INC | $36.90 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $29.83 | 2020 | |
| Edwards Lifesciences Corporation | $24.56 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $24.17 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.75 | 2022 | |
| Cmp Pharma, INC. | $15.59 | 2020 | |
| Boston Scientific Corporation | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oswald Bostic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.